Search clinical trials for: MABT5102A

Total 6 results

Genentech, Inc.
National Institute on Aging (NIA); Banner Alzheimer's Institute

Completed

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Alzheimer's Disease

Colombia
Hoffmann-La Roche
National Institute on Aging (NIA); Banner Alzheimer's Institute

Completed

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Alzheimer Disease

Colombia
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers

Healthy Volunteer
Genentech, Inc.

Completed

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Spain, United States, France
Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Alzheimer's Disease

United States, Spain, France, Canada, Germany, United Kingdom
Genentech, Inc.

Completed

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Healthy Volunteer

United States

3

Subscribe